Evidence mapPaperPMID 37872307Full record

ArticleHeart and vessels2024

Soluble ST2, BCN-Bio-HF calculator and MAGGIC-HF score in long-term risk prediction after an urgent visit for heart failure.

Teresa Miriam Pérez-Sanz, Itziar Gómez-Salvador, Pau Codina, Beatriz Calvo Antón, María Mar de la Torre Carpente, Belén Redondo Bermejo, Cristina Tapia Ballesteros

Abstract read
PubMed Publisher
In one paragraph

Article in Heart and vessels, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Teresa Miriam Pérez-SanzCardiology Service, University Hospital Río Hortega, Valladolid, Spain. tperezsa@saludcastillayleon.es.ORCID http://orcid.org/0000-0001-5945-3803
Itziar Gómez-SalvadorCardiology Service, CIBERCV (Biomedical Research Centre in the Cardiovascular Diseases Network), University Clinic Hospital, Valladolid, Spain.
Pau CodinaHeart Failure Clinic and Cardiology Service, University Hospital Germans Trias I Pujol, Badalona, Spain.
Beatriz Calvo AntónClinical Analysis Service, University Hospital Río Hortega, Valladolid, Spain.
María Mar de la Torre CarpenteCardiology Service, University Hospital Río Hortega, Valladolid, Spain.
Belén Redondo BermejoCardiology Service, University Hospital Río Hortega, Valladolid, Spain.
Cristina Tapia BallesterosCardiology Service, University Hospital Río Hortega, Valladolid, Spain.
Hospital Universitario Río Hortega · ESCentro de Investigación en Red en Enfermedades Cardiovasculares · ESUniversidad de Valladolid · ESUniversitat Autònoma de Barcelona · ES

Funding

Gerencia Regional de Salud de Castilla y León GRS 1077/A/15
6 · The paper itself

Abstract

Soluble ST2 (sST2) is the expression of a pathogenic process related to adverse remodeling that ultimately leads to increased mortality in heart failure (HF). Risk score models provide a comprehensive approach for mortality prediction, beyond the use of biomarkers alone. The objective was to determine the additional value of sST2 and two well-validated contemporary risk scores, BCN-Bio-HF and MAGGIC-HF, in predicting mortality and readmission in the acute setting. This prospective study included 129 patients (mean age 75 ± 9 years; 52% males) after an urgent HF visit. Baseline sST2 levels were measured and the two risk scores were calculated. The primary endpoint was all-cause mortality, and the secondary endpoint was HF readmissions. The follow-up period was 3.6 ± 1.9 years. Patients who died (46%) had higher sST2 concentrations (80.5 vs. 42.7 ng/ml; p < 0.001). The BCN-Bio-HF calculator with sST2 demonstrated the best discriminative ability for mortality prediction (area under the ROC curve: 0.792; p < 0.001). In multivariate analysis for each risk score, the MAGGIC-HF score retained its predictive value only in the model without sST2 (3-year risk: HR = 1.036; 95% CI 1.019-1.054; p < 0.001). However, the BCN-Bio-HF score maintained its prognostic value with sST2 (HR = 1.032; 95%CI 1.020-1.044; p < 0.001), as well as without sST2 (HR = 1.035; 95% CI 1.021-1.049; p < 0.001). sST2 was not associated with readmission, and only the BCN-Bio-HF risk of HF hospitalization showed independent predictive value (OR = 1.040; 95% CI 1.005-1.076; p = 0.023). For predicting long-term mortality in HF in the emergency department, the BCN-Bio-HF calculator with sST2 demonstrated superior discrimination and allows estimation of the risk of HF hospitalizations.

Indexed as

Heart FailureInterleukin-1 Receptor-Like 1 ProteinAgedAged, 80 and overBiomarkersFemaleHumansMaleNatriuretic Peptide, BrainPrognosisProspective StudiesBiomarkersInterleukin-1 Receptor-Like 1 ProteinNatriuretic Peptide, BrainHeart FailureRisk predictionST2Urgent visit

Identifiers

PMID37872307
OpenAlexW4387880586

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.